Skip to content

Intravenous Nalbuphine Versus Lidocaine for Prevention of Propofol Injection Pain

Comprasion of Intravenous Nalbuphine Versus Lidocaine in Reducing Propofol -Induced Injection Pain During General Surgery Procedure

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07422558
Enrollment
92
Registered
2026-02-20
Start date
2026-03-01
Completion date
2026-08-01
Last updated
2026-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Procedural Pain

Brief summary

Propofol is a commonly used intravenous anesthetic agent, but its administration is frequently associated with injection pain, causing patient discomfort and agitation. Various pharmacological agents have been used to reduce this pain, including nalbuphine and lidocaine; however, results from previous studies remain conflicting. This randomized clinical trial aims to compare the effectiveness of intravenous nalbuphine versus intravenous lidocaine in reducing the frequency of propofol-induced injection pain in patients undergoing elective general surgery procedures.

Detailed description

Propofol-induced injection pain is a common and undesirable adverse effect that can lead to patient distress during induction of anesthesia. Nalbuphine, a kappa-opioid receptor agonist and partial mu-opioid receptor antagonist, and lidocaine, a sodium channel blocker, have both been used to reduce this pain, but evidence regarding their comparative effectiveness remains inconsistent. This randomized clinical trial will be conducted in the Department of Anesthesiology, PGMI / Hayatabad Medical Complex, Peshawar. A total of 92 adult patients with ASA physical status I-II, scheduled for elective general surgery under general anesthesia, will be enrolled and randomized into two equal groups. Group A will receive intravenous nalbuphine at a dose of 0.1 mg/kg, while Group B will receive intravenous lidocaine at a dose of 4.5 mg/kg (maximum 300 mg), administered 60 seconds prior to induction with propofol. Injection pain will be assessed by the inducing anesthesiologist using a four-point pai

Interventions

DRUGNalbuphine

Intravenous nalbuphine 0.1mg/kg administred 60second prior to induction with propofol

DRUGLidocaine

Intravenous lidocaine 4.5mg/kg (maximum 300mg) administred 60sec prior to induction with propofol

Sponsors

Hayatabad Medical Complex
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Age 18-60 years * Either male or female * ASA physical status I or II * Scheduled for elective general surgery under general anesthesia using propofol

Exclusion criteria

* Known hypersensitivity to propofol, nalbuphine, or lidocaine * Emergency surgery * Use of analgesics prior to surgery * Pregnant women * Lactating women

Design outcomes

Primary

MeasureTime frameDescription
Frequency of propofol- induced injection painDuring induction of anesthesia (within 1-2 minutes of propofol administrationPresence of injection pain assessed using a four-point pain scale during propofol injection until loss of eyelash reflex. Pain score ≥1 will be considered as presence of injection pain.

Contacts

CONTACTDr.Arina kore Trainee medical officer, MBBS
Kore2k15@gmail.com+923446835431
PRINCIPAL_INVESTIGATORDr.Arina kore Trainee medical officer, MBBS

PGMI/Hayatabad Medical complex(HMC),Peshawar

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026